127-LB: Real-World A1C Changes and Prescribing Provider Types among T2DM Patients Initiating Treatment with Oral Semaglutide

127-LB: Real-World A1C Changes and Prescribing Provider Types among T2DM Patients Initiating Treatment with Oral Semaglutide

Purpose: To describe A1c changes and characteristics of patients with type 2 diabetes mellitus (T2DM) initiating oral semaglutide (sema) , by baseline A1c ≥9% and

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Diabetes (New York, N.Y.) N.Y.), 2022-06, Vol.71 (Supplement_1)
Hauptverfasser: FRAZER, MONICA S., SWIFT, CAROLINE, LESZKO, MICHAEL, SARGENT, ANDREW, BUYSMAN, ERIN, ALVAREZ, SARA B., NOONE, JOSHUA, GUEVARRA, MICO
Format: Artikel
Sprache:eng
Schlagworte:
Antidiabetics
Diabetes
Diabetes mellitus (non-insulin dependent)
Patients
Primary care
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Purpose: To describe A1c changes and characteristics of patients with type 2 diabetes mellitus (T2DM) initiating oral semaglutide (sema) , by baseline A1c ≥9% and
ISSN:0012-1797
1939-327X
DOI:10.2337/db22-127-LB